Sage said in an SEC filing that it expects a non-recurring charge tied to the workforce reduction of $26 million to $28 ...

Several executives will depart as part of the changes, including Anne Marie Cook, Kimi Iguchi, Matt Lasmanis, Heinrich ...

Sage Therapeutics Inc.’s stock slid 4.7% Thursday, after the biotech said it’s cutting about 33% of its workforce as part of ...

Sage Therapeutics, Inc. (Nasdaq: SAGE), today announced a strategic reorganization of its business operations to support the ongoing launch of ZURZUVAE in postpartum depression and focus pipeline ...

Talkiatry partnership resembles efforts by pharma companies like Eli Lilly and Pfizer to team up with telehealth companies.

Sage and Biogen last year won Food and Drug Administration approval of Zurzuvae as the first pill to treat postpartum depression, but the agency rejected the drug for major depressive disorder, a much ...

The FDA approved Zurzuvae as the first oral therapy for post-partum depression (PPD) in August 2023, although, the agency ...

Sage and Biogen will continue to partner on ZURZUVAE® (zuranolone), the first and only FDA-approved oral treatment for women with postpartum depression (PPD) and will continue to work on their ...

The companies will continue to collaborate on Zurzuvae, the FDA-approved treatment for postpartum depression. The companies recently announced negative results from the Phase 2 KINETIC 2 Study of ...